Exparel Transversus Abdominis Plane Block vs Intrathecal Analgesia In Colorectal Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02356198
Recruitment Status : Completed
First Posted : February 5, 2015
Last Update Posted : October 18, 2017
Information provided by (Responsible Party):
Dorin T. Colibaseanu, M.D., Mayo Clinic

Brief Summary:
This study is prospective, randomized trial in which EXPAREL TAP block is compared to standard IT opioid administration, in relieving postoperative pain, decreasing length of stay, and use of narcotic medication.

Condition or disease Intervention/treatment Phase
Conditions Requiring Colorectal Surgery Drug: EXPAREL Drug: Intrathecal hydromorphone Not Applicable

Detailed Description:

Primary Objective To assess efficacy of EXPAREL TAP blocks in improving pain scores for 48 hours postoperatively, and in reducing total oral morphine equivalents (OME) use, compared to standard Intrathecal opioid administration (IT).

Secondary Objective Assess the length of stay (LOS), postoperative ileus (POI) incidence, and the use of intravenous patient controlled analgesia (PCA) in patients that had EXPAREL TAP blocs compared to IT.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Exparel Transversus Abdominis Plane Block vs Intrathecal Analgesia In Colorectal Surgery: A Prospective Randomized Trial
Study Start Date : March 2015
Actual Primary Completion Date : October 2017
Actual Study Completion Date : October 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: TAP block (EXPAREL)
After induction of anesthesia, the patients will receive a single injection with 133 mg of EXPAREL in the transversus abdominis plane (TAP), on each side, suspended in 20mL of injectable saline.
transversus abdominis plane injection
Other Name: liposomal bupivacaine

Active Comparator: IT
single injection intrathecal hydromorphone analgesia given preoperatively
Drug: Intrathecal hydromorphone
Intrathecal opioid administration
Other Name: dilaudid

Primary Outcome Measures :
  1. Pain scores [ Time Frame: First 48 hours post op. ]
    mean pain scores for 48 hours after surgery.

Secondary Outcome Measures :
  1. Length of stay [ Time Frame: Post operative ]
    Length of stay days post operative.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • • All patients undergoing elective laparoscopic or open colorectal resections who are eligible for IT, and able to be enrolled in ERP.

    • Age >18 years
    • BMI <40
    • Ability to understand and read English

Exclusion Criteria:

  • • Not able or unwilling to sign consent.

    • Currently pregnant or lactating.
    • Patients with chronic pain, requiring daily opiate use at time of surgery.
    • Patients intolerant of opiates, NSAIDS, acetaminophen or local anesthetics.
    • Patients requiring emergent surgery.
    • Abdominoperineal resections
    • Any contraindications to neuraxial analgesia (coagulopathy, localized infection at the potential site of injection, pre-existing spinal canal pathology)
    • Patients with a diagnosis of inflammatory bowel disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02356198

United States, Florida
Mayo Clinic Florida
Jacksonville, Florida, United States, 32224
Sponsors and Collaborators
Mayo Clinic

Responsible Party: Dorin T. Colibaseanu, M.D., PI, Mayo Clinic Identifier: NCT02356198     History of Changes
Other Study ID Numbers: 14-003143
First Posted: February 5, 2015    Key Record Dates
Last Update Posted: October 18, 2017
Last Verified: October 2017

Additional relevant MeSH terms:
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents